单位:[1]Department of Medicine, Duke University School of Medicine, Durham, NC 27710, United States[2]Pharmacology Department, JOINN Laboratories Inc., Suzhou 215421, China[3]Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, United States[4]Department of Respiratory Medicine, China–Japan Friendship Hospital, Beijing 100013, China[5]Department of Respiratory Medicine, The First Affiliated Hospital, Zhejiang University, Hangzhou 310006, China浙江大学医学院附属第一医院
Dysregulated repair of lung injury often results in lung fibrosis characterized by unremitting deposition of matrix components including glycosaminoglycan hyaluronan (HA). HA is mainly produced by hyaluronan synthases (HAS) in mesenchymal cells. We previously demonstrated that over-expression of HAS2 in mesenchymal cells in mice regulates the invasiveness of fibroblasts and promotes severe lung fibrosis. The mechanisms that control the resolution of lung fibrosis are unknown. We propose that a critical step in resolving fibrosis is the induction of senescence in fibrotic fibroblasts and hyaluronan synthase 2 may regulate this process. We found that fibrotic fibroblasts developed the characteristics of replicative senescence in culture and that HAS2 expression was dramatically down-regulated. Furthermore, down-regulation of HAS2 initiated and regulated fibroblast senescence through a p27-CDK2-SKP2 pathway. Deletion of HAS2 in mouse mesenchymal cells increased the cellular senescence of fibroblasts in bleomycin-induced mouse lung fibrosis in vivo. These data suggest that HAS2 may be a critical regulator of the fate of pulmonary fibrosis and we propose a model where over-expression of HAS2 promotes an invasive phenotype resulting in severe fibrosis and down-regulation of HAS2 promotes resolution. Targeting HAS2 to induce fibroblast senescence could be an attractive approach to resolve tissue fibrosis. (C) 2016 The Authors. Published by Elsevier B.V.
基金:
National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AI052201, HL060539, P01 HL108793, HL122068]; CIRMCalifornia Institute for Regenerative Medicine [RB5-07302]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL060539, P01HL108793, R01HL122068, P50HL084917] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI052201] Funding Source: NIH RePORTER
第一作者单位:[1]Department of Medicine, Duke University School of Medicine, Durham, NC 27710, United States[2]Pharmacology Department, JOINN Laboratories Inc., Suzhou 215421, China
通讯作者:
通讯机构:[3]Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, United States[*1]Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, United States
推荐引用方式(GB/T 7714):
Li Yuejuan,Liang Jiurong,Yang Ting,et al.Hyaluronan synthase 2 regulates fibroblast senescence in pulmonary fibrosis[J].MATRIX BIOLOGY.2016,55:35-48.doi:10.1016/j.matbio.2016.03.004.
APA:
Li, Yuejuan,Liang, Jiurong,Yang, Ting,Mena, Jessica Monterrosa,Huan, Caijuan...&Noble, Paul W..(2016).Hyaluronan synthase 2 regulates fibroblast senescence in pulmonary fibrosis.MATRIX BIOLOGY,55,